Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
OnKure Therapeutics, Inc. issued 26,713,636 shares of common stock to institutional accredited investors for $4.15 per Share.
- Security
- common stock
- Shares
- 26,713,636 shares
- Purchaser
- institutional accredited investors
- Consideration
- $4.15 per Share
Exact text from the filing
the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
OnKure Therapeutics, Inc. issued pre-funded warrants to purchase 9,430,959 shares of Common Stock of warrant to institutional accredited investors for $4.1499 per underlying Warrant Share.
- Security
- warrant
- Shares
- pre-funded warrants to purchase 9,430,959 shares of Common Stock
- Purchaser
- institutional accredited investors
- Consideration
- $4.1499 per underlying Warrant Share
Exact text from the filing
pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors
- Value
- approximately $150.0 million
- Effective
- 2026-03-27
Exact text from the filing
On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Company and the Investors
- Effective
- 2026-03-27
Exact text from the filing
the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.
View on SEC.gov